This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Large Drug Stocks to Watch in a Booming Industry
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Beat the Market Like Zacks: Novo Nordisk, Axon, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
by Zacks Equity Research
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
The Zacks Analyst Blog Highlights Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works
by Zacks Equity Research
Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works are included in this Analyst Blog.
Top Research Reports for Novo Nordisk, Amgen & ADP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Amgen Inc. (AMGN) and Automatic Data Processing, Inc. (ADP).
BAYRY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAYRY vs. NVO: Which Stock Is the Better Value Option?
Beat the Market Like Zacks: JPMorgan, Berkshire Hathaway, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
Company News for Nov 3, 2022
by Zacks Equity Research
Companies In The News Are: CVS, HUM, ETR, NVO.
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
BAYRY or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BAYRY vs. NVO: Which Stock Is the Better Value Option?
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
by Zacks Equity Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
by Zacks Equity Research
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
The Zacks Analyst Blog Highlights Novo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron
by Zacks Equity Research
Novo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron are included in this Analyst Blog.
Top Analyst Reports for Novo Nordisk, Suncor Energy, & Nasdaq
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ).
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
by Zacks Equity Research
Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.
Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition
by Zacks Equity Research
Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.
The Zacks Analyst Blog Highlights General Motors, Ford , Honda, Toyota and Stellantis
by Zacks Equity Research
General Motors, Ford , Honda, Toyota and Stellantis are part of The Zacks Analyst Blog.
Top Stock Reports for Microsoft, Amazon.com & Walmart
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and Walmart Inc. (WMT).
Beat the Market Like Zacks: Avis Budget Group (CAR), Deere (DE), Novo Nordisk (NVO) in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our last week's achievements.
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema
by Zacks Equity Research
Novo Nordisk (NVO) completes the phase II study evaluating CagriSema, a combination of semaglutide and cagrilintide for treating type II diabetes.
Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.